These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22083481)

  • 1. Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors.
    McFadden K; Fletcher P; Rossi F; Kantharaju ; Umashankara M; Pirrone V; Rajagopal S; Gopi H; Krebs FC; Martin-Garcia J; Shattock RJ; Chaiken I
    Antimicrob Agents Chemother; 2012 Feb; 56(2):1073-80. PubMed ID: 22083481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The active core in a triazole peptide dual-site antagonist of HIV-1 gp120.
    Umashankara M; McFadden K; Zentner I; Schön A; Rajagopal S; Tuzer F; Kuriakose SA; Contarino M; Lalonde J; Freire E; Chaiken I
    ChemMedChem; 2010 Nov; 5(11):1871-9. PubMed ID: 20677318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introducing metallocene into a triazole peptide conjugate reduces its off-rate and enhances its affinity and antiviral potency for HIV-1 gp120.
    Gopi H; Cocklin S; Pirrone V; McFadden K; Tuzer F; Zentner I; Ajith S; Baxter S; Jawanda N; Krebs FC; Chaiken IM
    J Mol Recognit; 2009; 22(2):169-74. PubMed ID: 18498083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-natural peptide triazole antagonists of HIV-1 envelope gp120.
    Kamanna K; Aneja R; Duffy C; Kubinski P; Rodrigo Moreira D; Bailey LD; McFadden K; Schön A; Holmes A; Tuzer F; Contarino M; Freire E; Chaiken IM
    ChemMedChem; 2013 Feb; 8(2):322-8. PubMed ID: 23239505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption.
    Emileh A; Tuzer F; Yeh H; Umashankara M; Moreira DR; Lalonde JM; Bewley CA; Abrams CF; Chaiken IM
    Biochemistry; 2013 Apr; 52(13):2245-61. PubMed ID: 23470147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
    Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
    J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Discovery and Development of Oxalamide and Pyrrole Small Molecule Inhibitors of gp120 and HIV Entry - A Review.
    Motati DR; Uredi D; Watkins EB
    Curr Top Med Chem; 2019; 19(18):1650-1675. PubMed ID: 31424369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Aminothiazolones as anti-HIV agents that act as gp120-CD4 inhibitors.
    Tiberi M; Tintori C; Ceresola ER; Fazi R; Zamperini C; Calandro P; Franchi L; Selvaraj M; Botta L; Sampaolo M; Saita D; Ferrarese R; Clementi M; Canducci F; Botta M
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3043-52. PubMed ID: 24614386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators.
    Zhang S; Holmes AP; Dick A; Rashad AA; Enríquez Rodríguez L; Canziani GA; Root MJ; Chaiken IM
    Retrovirology; 2021 Oct; 18(1):31. PubMed ID: 34627310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1.
    Gopi H; Umashankara M; Pirrone V; LaLonde J; Madani N; Tuzer F; Baxter S; Zentner I; Cocklin S; Jawanda N; Miller SR; Schön A; Klein JC; Freire E; Krebs FC; Smith AB; Sodroski J; Chaiken I
    J Med Chem; 2008 May; 51(9):2638-47. PubMed ID: 18402432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.
    Rosemary Bastian A; Nangarlia A; Bailey LD; Holmes A; Kalyana Sundaram RV; Ang C; Moreira DR; Freedman K; Duffy C; Contarino M; Abrams C; Root M; Chaiken I
    J Biol Chem; 2015 Jan; 290(1):529-43. PubMed ID: 25371202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-free HIV-1 virucidal action by modified peptide triazole inhibitors of Env gp120.
    Bastian AR; Kantharaju ; McFadden K; Duffy C; Rajagopal S; Contarino MR; Papazoglou E; Chaiken I
    ChemMedChem; 2011 Aug; 6(8):1335-9, 1318. PubMed ID: 21714095
    [No Abstract]   [Full Text] [Related]  

  • 13. Recent Progress in the Development of HIV-1 Entry Inhibitors: From Small Molecules to Potent Anti-HIV Agents.
    Suttisintong K; Kaewchangwat N; Thanayupong E; Nerungsi C; Srikun O; Pungpo P
    Curr Top Med Chem; 2019; 19(18):1599-1620. PubMed ID: 31424370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions.
    Qi Q; Wang Q; Chen W; Du L; Dimitrov DS; Lu L; Jiang S
    Emerg Microbes Infect; 2017 Jun; 6(6):e59. PubMed ID: 28634358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1.
    Lai W; Huang L; Ho P; Li Z; Montefiori D; Chen CH
    Antimicrob Agents Chemother; 2008 Jan; 52(1):128-36. PubMed ID: 17954689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C.
    Férir G; Palmer KE; Schols D
    Virology; 2011 Sep; 417(2):253-8. PubMed ID: 21802104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide triazole inactivators of HIV-1: how do they work and what is their potential?
    Chaiken I; Rashad AA
    Future Med Chem; 2015; 7(17):2305-10. PubMed ID: 26599515
    [No Abstract]   [Full Text] [Related]  

  • 18. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
    Murga JD; Franti M; Pevear DC; Maddon PJ; Olson WC
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3289-96. PubMed ID: 17005807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
    Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
    FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide and non-peptide HIV fusion inhibitors.
    Jiang S; Zhao Q; Debnath AK
    Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.